



CASE LD0276 NP

### CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Carrie A. Shaw

Type or print name

\_\_\_\_

05/18/04

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

VITE ET AL.

APPLICATION NO: 10/736476 FILED: DECEMBER 15, 2003

FOR: C-6 MODIFIED INDAZOLYLPYRROLOTRIAZINES

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

Applicants also call the Examiner's attention to the following U.S. Applications, copies of which are available upon request:

| <b>Application No.</b> | Filing Date | BMS Docket No. | <u>Status</u> | Publication No. |
|------------------------|-------------|----------------|---------------|-----------------|
| 10/289,010             | 11/06/02    | QA237A CIP 1   | Pending       | US20030186982A1 |
| 09/753,829             | 05/18/00    | LD170 NP       | Pending       |                 |
| 10/294,281             | 11/14/02    | LD280 NP       | Pending       | US20030186983A1 |
| 10/623,171             | 07/18/03    | LD310 NP       | Pending       | US20040072832A1 |
| 10/420,399             | 04/22/03    | QA267 NP       | Pending       |                 |
| 10/420,445             | 04/22/03    | QA270 NP       | Pending       | US20030232831A1 |
| 10/440,864             | 05/19/03    | QA272 NP       | Pending       | US20040023992A1 |

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 609-252-4741

May 18, 2004

Date:

Elliott Korsen

**Attorney for Applicants** 

Reg. No. 32,705

FÔRM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

## **INFORMATION DISCLOSURE CITATION**

(Upe several sheets if necessary)

ATTY. DOCKET NO. LD0276 NP APPLICATION NO. 10/736476 APPLICANT VITE ET AL. FILING DATE DECEMBER 15, 2003

Group

| WW I     | ,        | 9  | 11.6        | DATENT DOCUMENTS                        |             |            |             | -              |
|----------|----------|--|-------------|---|-------------|------------|-------------|----------------|
| EXAMINER | MAL      |  | <del></del> | PATENT DOCUMENTS                        | <del></del> |            |             |                |
| INITIAL  | -        | DOCUMENT NUMBER  | DATE        | NAME                                    | CLA         | ASS SUBCLA | SS F        | ILING DATE     |
|          | AA       | 4,908,056  | 3/13/90     | Tseng                                   |             |            |             |                |
|          | AB       |  |             |   |             |            |             | <del></del>    |
|          | AC       |  |             |   |             |            |             |                |
|          | AD       |  |             |   |             |            | $\perp$     |                |
|          | AE       |  |             |   |             |            | $\perp$     |                |
|          | AF       |  |             |   |             |            |             | <del> </del>   |
|          | AG       |  |             |   |             |            |             |                |
|          | АН       |  |             |   |             |            |             |                |
|          | Al       |  |             |   |             |            |             |                |
|          | AJ       |  |             |   |             |            |             |                |
|          | AK       |  |             |   |             |            |             |                |
|          | AL       |  |             |   |             |            |             |                |
|          |          |  | FOREIG      | ON PATENT DOCUMENTS                     |             |            |             |                |
|          |          | DOCUMENT NUMBER  | DATE        | OFFICE                                  | CLASS       | SUBCLASS   | TRAN<br>YES | ISLATION<br>NO |
|          | АМ       | WO 98/08847  | 3/5/98      | PCT                                     |             |            |             |                |
|          | AN       | EP 778 277 A1  | 6/11/97     | PCT                                     |             |            |             |                |
|          | AO       | WO 01/14378  | 1/3/01      | PCT (in Japanese w/translation)         |             |            |             |                |
|          | AP       |  |             |   |             |            |             |                |
|          | AQ       |  |             |   |             |            |             |                |
|          | <u> </u> | OTHER DOC  | UMENTS      | (Including Author, Title, Date, Pertine | nt pages, E | tc.)       | J           |                |
|          | AR       | Otter et al., "Conformational Properties of Purine-Like C-Nucleosides", Nucleoside & Nucleotides, Vol. 15, Nos. 1-3, pgs. 793-807 (1996)   |             |   |             |            |             |                |
|          | AS       | Quintella et al., "A Ready One-Pot Preparation for Pyrrolo [2,1-fl-[1,2,4] Triazine and Pyrazolo[5,1-c]Pyramidol[4,5-e]-[1,2,4]Triazine Derivatives", Tetrahedron, Vol. 52, No. 8, pgs. 3037-3048 (1996) |             |   |             |            |             |                |
|          | АТ       | Patil et al., "Synthesis of Pyrrolo [2,1-f][1,2,4] Triazine Congeners of Nucleic Acid Purines via the N-Amination of 2-Substituted Pyrroles [1]", J. Heterocyclic Chem. Vol. 31, No. 4, 781-807 (1994)   |             |   |             |            |             |                |
| EXAMIN   | ER       |  |             | DATE CONSIDERED                         | <del></del> |            |             |                |

<sup>\*</sup>EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

# **INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO. LD0276 NP APPLICATION NO. 10/736476 APPLICANT VITE ET AL. FILING DATE DECEMBER 15, 2003

Group

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

|          | AA | Neunhoeffer et al., "Cycloadditionen mit Methoxy-und Dialkylamino-1,2,4-Triazinen", Justus Liebigs Ann. Chem., Vol. 9, pgs. 1413-1420 (1977) & Chem. Abstract 88:121113q, (1978) |                                     |                       |  |  |  |
|----------|----|--|-------------------------------------|-----------------------|--|--|--|
|          | AB | Skobe et al., "Halting Angiogenesis Si<br>3, No. 11, pgs. 1223-1227 (1997)   | uppresses Carcinoma Cell Invasion". | Nature Medicine, Vol. |  |  |  |
|          | AC |  |                                     |                       |  |  |  |
|          | AD |  |                                     |                       |  |  |  |
|          | AE |  |                                     |                       |  |  |  |
|          | AF |  |                                     |                       |  |  |  |
|          | AG | ,  |                                     |                       |  |  |  |
|          | АН |  |                                     |                       |  |  |  |
|          | Al |  |                                     |                       |  |  |  |
|          | AJ | ,  |                                     |                       |  |  |  |
|          | AK |  |                                     |                       |  |  |  |
|          | AL |  |                                     |                       |  |  |  |
| ·        | AM |  |                                     |                       |  |  |  |
|          | AN |  |                                     |                       |  |  |  |
| EXAMINER | }  |  | DATE CONSIDERED                     |                       |  |  |  |

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.